Wound Series Part 2c: Wound Bed Cleansing

Contact Hour(s): 

1 Contact Hour

Author: 

Linda J. Cowan, PHD, ARNP, FNP-BC, CWS

Alyssa King, DNP, APRN, CPNP-PC, PMHNP-BC, PMH-C, CLC, CNE

This peer-reviewed course is applicable for the following professions: 

Advanced Practice Registered Nurse (APRN), Certified Nurse Practitioner, Licensed Practical Nurse (LPN), Licensed Vocational Nurses (LVN), Nursing Student, Occupational Therapist (OT), Occupational Therapist Assistant (OTA), Registered Nurse (RN), Registered Nurse Practitioner

Accreditations: 

The American Nurses Credentialing Center (ANCC), The American Occupational Therapy Association (AOTA),

State Approvals: 

Alabama, Provider #ABNP1485; California BRN Provider #CEP # 13509; Kentucky Board of Nursing Provider #7-0085; Florida Board of Nursing Provider 50-353;

Course Description: 

This course discusses pain management considerations prior to wound cleansing and debridement, a brief review of the TIME mnemonic from the prior course (Wound Series 2b: Wound Care), a more in-depth breakdown of this mnemonic to emphasize common debridement methods and how to differentiate inflammation of a wound versus an active infection, and an explanation of how to determine when it is appropriate to utilize antimicrobial wound cleansing solutions versus less cytotoxic methods.

Outcomes: 

≥ 92% of participants will know the process of proper wound bed cleansing.

Objectives:

After completing this continuing education course, the participant will be able to meet the following objectives:

1. Identify considerations for pain management prior to wound cleansing and debridement.
2. Utilize the TIME mnemonic to assess the wound prior to cleansing.
3. Describe wound debridement methods.
4. Differentiate wound inflammation from infection.
5. Determine when it is appropriate to use antimicrobial wound cleansing solutions.

Disclosures: 

CEUFast Inc. and the course planning team for this educational activity do not have any relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.